2025 research highlights
In 2025 alone, more than 350 new scientific papers were published attesting to the wide-ranging bioactive properties of fucoidans. Marinova continues to lead global research into fucoidan, expanding its own R&D program in addition to supplying high purity fucoidans for innovative studies by independent researchers.
A summary of recent findings utilising Marinova's fucoidan extracts is provided below.
Gut health
As reported in Vitafoods Insights, new evidence has emerged into the significant gut health benefits of high purity fucoidan from the brown seaweed Undaria pinnatifida (Wimmer, 2025). Stool samples from healthy human donors were utilised within a validated in vitro gut model known as the SHIME® (Simulator of the Human Intestinal Microbial Ecosystem) model. Following a three-week supplementation with fucoidan, the model explored both colonic microbiome activity and composition, along with the quantification of short-chain fatty acids.
Key findings included:
- Enriched microbial diversity
- Increased species richness
- Increased short-chain fatty acids
- Demonstrated benefits from an extended fermentation period
Neuroprotective and anti-inflammatory activity
Marinova’s research program also included investigations into neuroprotective and anti-inflammatory activity of Undaria pinnatifida fucoidan (Yang 2025a; Yang 2025b). Research not only showed significant reductions in the expression of pro-inflammatory cytokines and modulation of proteins involved in oxidative stress and neuroinflammation, but outlined exciting future research directions including clinical translation in the fields of inflammation and brain health.
Prostate health
Building on exciting 2024 results from an investigation into benign prostatic hyperplasia (BPH) in an animal model (Shanmugasundaram, 2024), Marinova has recently completed a clinical trial. Results of this double blind, placebo-controlled study are expected early in 2026 and will be of significant interest to brands serving the growing men’s health category. With limited clinically proven ingredients currently available, data to support the entry of fucoidan into the prostate health category is highly anticipated.
Independent research
Marinova also provides high purity fucoidan samples to other innovative research groups. A selection of recently published studies utilising the company’s unique extracts includes:
Biomedical implants: Enhancing the performance of titanium-based implants
Antibiotic protection: Combatting the disturbance of gut microbiota
Osteoarthritis: Nanoparticles and hydrogels to transport fucoidan to injured cartilage
Gum disease: Utilisation of nanoparticles to protect against periodontal pathogen
Motor neuron injury: Improving the function of damaged motor neurons
A comprehensive overview of Marinova's research is available in the company's latest white paper. Request a copy here.